Integrated Quantitative Investments LLC Takes Position in Privia Health Group, Inc. $PRVA

Integrated Quantitative Investments LLC acquired a new position in Privia Health Group, Inc. (NASDAQ:PRVA) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 46,878 shares of the company’s stock, valued at approximately $1,078,000.

Other hedge funds also recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in Privia Health Group by 6.3% in the second quarter. Geode Capital Management LLC now owns 2,655,569 shares of the company’s stock valued at $61,086,000 after acquiring an additional 158,521 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Privia Health Group by 180.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,633,040 shares of the company’s stock valued at $59,112,000 after purchasing an additional 1,693,870 shares during the last quarter. Van Berkom & Associates Inc. purchased a new stake in shares of Privia Health Group during the 1st quarter valued at about $45,207,000. Northern Trust Corp lifted its stake in shares of Privia Health Group by 2.2% in the 1st quarter. Northern Trust Corp now owns 1,423,865 shares of the company’s stock worth $31,966,000 after purchasing an additional 31,224 shares during the period. Finally, Nuveen LLC purchased a new position in shares of Privia Health Group in the first quarter worth approximately $26,899,000. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Barclays upped their target price on shares of Privia Health Group from $22.00 to $23.00 and gave the company an “equal weight” rating in a report on Monday, November 10th. Weiss Ratings restated a “hold (c)” rating on shares of Privia Health Group in a research note on Thursday. Citigroup reiterated an “outperform” rating on shares of Privia Health Group in a research report on Friday, August 29th. Stephens reissued an “overweight” rating and set a $32.00 price target on shares of Privia Health Group in a report on Wednesday, September 24th. Finally, Zacks Research raised Privia Health Group from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 19th. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Privia Health Group has an average rating of “Moderate Buy” and an average target price of $30.00.

Privia Health Group Stock Down 1.3%

NASDAQ:PRVA opened at $23.45 on Friday. The business’s 50-day simple moving average is $24.21 and its two-hundred day simple moving average is $22.79. Privia Health Group, Inc. has a 52 week low of $18.77 and a 52 week high of $26.51. The stock has a market cap of $2.88 billion, a PE ratio of 180.40, a P/E/G ratio of 3.91 and a beta of 0.83.

Privia Health Group (NASDAQ:PRVA) last released its earnings results on Tuesday, June 7th. The company reported $0.10 earnings per share (EPS) for the quarter. The firm had revenue of $213.61 million during the quarter. Privia Health Group had a return on equity of 2.52% and a net margin of 0.89%. Sell-side analysts anticipate that Privia Health Group, Inc. will post 0.14 earnings per share for the current fiscal year.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.